

Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice

著者	Jin Ingji, Shimada Tsutomu, Yokogawa Koichi, Nomura Masaaki, Ishizaki Junko, Piao Yingshi, Kato Yukio, Tsuji Akira, Miyamoto Kenichi
journal or publication title	Biochemical Pharmacology
volume	72
number	8
page range	1042-1050
year	2006-10-01
URL	<a href="http://hdl.handle.net/2297/2958">http://hdl.handle.net/2297/2958</a>

available at [www.sciencedirect.com](http://www.sciencedirect.com)journal homepage: [www.elsevier.com/locate/biochempharm](http://www.elsevier.com/locate/biochempharm)

# Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice

Mingji Jin<sup>a</sup>, Tsutomu Shimada<sup>a</sup>, Koichi Yokogawa<sup>a,b</sup>, Masaaki Nomura<sup>a</sup>, Junko Ishizaki<sup>a</sup>, Yingshi Piao<sup>c</sup>, Yukio Kato<sup>a</sup>, Akira Tsuji<sup>a</sup>, Ken-Ichi Miyamoto<sup>a,b,\*</sup>

<sup>a</sup>Graduate School of Natural Science and Technology, Kanazawa University, Kakuma, Kanazawa 920-1192, Japan

<sup>b</sup>Department of Hospital Pharmacy, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan

<sup>c</sup>Department of Molecular Pharmacology, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8640, Japan

## ARTICLE INFO

### Article history:

Received 10 May 2006

Accepted 21 July 2006

### Keywords:

Cyclosporin A

Bioavailability

P-glycoprotein

Dexamethasone

CYP3A

*In situ* loop

*mdr1a/1b* knockout mice

## ABSTRACT

We examined whether the oral bioavailability of cyclosporin A is controlled primarily by P-glycoprotein (P-gp) or CYP3A in the small intestine. *In situ* loop method was used to evaluate the uptake of cyclosporin A (40 nmol) at the upper and lower intestine of wild-type and *mdr1a/1b* knockout mice treated or not treated with dexamethasone (75 mg/kg/day, 7 days, i.p.). Expression of CYP3A mRNA in the control group was higher in the upper than the lower intestine, while that of the multidrug resistance-1a (*mdr1a*) mRNA was in the opposite order. Dexamethasone administration potently induced CYP3A and *mdr1a* mRNAs in the lower and upper intestine, respectively. At 45 min after cyclosporin A administration into an upper intestinal loop of the control group of wild-type mice, the ratio of residual cyclosporin A to dose did not differ significantly from that of *mdr1a/1b* knockout mice, whereas in dexamethasone-treated wild-type mice, the residual ratio was increased significantly. The ratio of the cyclosporin A metabolite M17 to cyclosporin A in portal venous blood at an upper intestinal loop of *mdr1a/1b* knockout mice was much higher than that a lower intestinal loop. The M17/cyclosporin A ratio of portal venous blood at a lower intestinal loop in *mdr1a/1b* knockout mice was increased significantly by dexamethasone treatment. These results suggest that, under physiological conditions, the oral bioavailability of cyclosporin A is mainly controlled by CYP3A in the upper intestine, rather than liver, but when P-gp is induced by steroid, the intestinal absorption of cyclosporin A may be inhibited.

© 2006 Published by Elsevier Inc.

## 1. Introduction

To determine appropriate dosage schedules of an immunosuppressant cyclosporin A for patients after transplantation, it is necessary to clarify the reason why the blood concentration

of cyclosporin A is frequently unstable [1–3]. It is suggested that P-glycoprotein (P-gp) and/or CYP3A limit the oral bioavailability of digoxin, rifampin [4], vinblastine [5], dexamethasone tromethorphan [6], tacrolimus [7], sirolimus [8] and cyclosporin A [9,10]. Lown et al. [11] suggested that

\* Corresponding author at: Department of Hospital Pharmacy, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan. Tel.: +81 76 265 2045; fax: +81 76 234 4280.

E-mail address: [miyaken@pharmacy.m.kanazawa-u.ac.jp](mailto:miyaken@pharmacy.m.kanazawa-u.ac.jp) (K.-I. Miyamoto).

0006-2952/\$ – see front matter © 2006 Published by Elsevier Inc.

doi:10.1016/j.bcp.2006.07.020

intestinal P-gp, rather than intestinal CYP3A, plays a key role in the interpatient variation in oral bioavailability of cyclosporin A. On the other hand, CYP3A accounts for about 30 and 70% of total CYP activity in the liver and small intestine, respectively [12–14], and intestinal first-pass metabolism mediated by CYP3A has been shown to be clinically relevant for several drugs, including cyclosporin A [15,16]. However, it remains to be fully clarified whether P-gp and/or CYP3A controls the oral bioavailability of cyclosporin A by limiting absorption from the small intestine.

We have reported that the blood concentrations of cyclosporin A [17] and tacrolimus [18] were decreased by combined steroid hormones due to induction of P-gp and/or CYP3A in the liver and small intestine. Hsiu et al. [19] also suggested that quercetin significantly decreased the oral bioavailability of cyclosporin A by inducing P-gp and/or CYP3A4. Further, Konishi et al. [20] demonstrated that the oral bioavailability of cyclosporin A is decreased by methylprednisolone, and the mechanism involves enhancement of small-intestinal P-gp function. Based on a study comparing the effects of high-dose dexamethasone (75 mg/kg/day intraperitoneally, for 7 days) in *mdr1a/1b* knockout mice and wild-type mice, we concluded that P-gp plays only a small role in the absorption of cyclosporin A under physiological conditions, but after induction by dexamethasone, P-gp functions as an absorption barrier to cyclosporin A in the small intestine [21]. In the present study, we used an *in situ* intestinal loop method to examine in detail the effects of both P-gp and CYP3A on the absorption of cyclosporin A from the upper and lower small intestine in wild-type and *mdr1a/1b* knockout mice treated with or without dexamethasone.

## 2. Materials and methods

### 2.1. Materials

Sandimmun® injection (cyclosporin A) and dexamethasone were purchased from Novartis Pharma Co. Ltd. (Tokyo, Japan) and Wako Pure Chemical Industries (Osaka, Japan), respectively. A cyclosporin A metabolite (M17), was supplied by Shiseido Co. Ltd. (Tokyo, Japan). Other reagents were purchased from Sigma Co. (St. Louis, MO).

### 2.2. Animal preparation

All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Kanazawa University. Experiments were performed on male *mdr1a/1b* knockout mice (body weight 22–27 g, Taconic Farms Inc., NY, USA). We used male FVB/NJcl mice (body weight 23–26 g, SLC, Hamamatsu, Japan) as the control wild-type mice. Mice were intraperitoneally injected daily for 7 days with a corn oil solution of dexamethasone (75 mg/kg/day). The control mice were intraperitoneally injected daily for 7 days with corn oil alone. Mice were fasted for 12 h prior to administration of cyclosporin A into a small intestinal loop, but water was freely available.

### 2.3. *In situ* absorption experiments

The *in situ* closed loop experiments were performed according to Bronner and Yost [22]. Following anesthetization of mice by intraperitoneal injection of sodium pentobarbital (50 mg/kg, Sigma Co.), the abdomen was opened by a midline longitudinal incision and a 5 cm upper (duodenum, jejunum) or lower (ileum) segment was isolated on a thermostatically controlled board at 37 °C. For the upper segment, we used 5 cm of upper small intestine from the pylorus, because the duodenum of mouse is short. The segment was rinsed with MES buffer (5 mM KCl, 100 mM NaCl, 10 mM MES, 85 mM mannitol, 0.01% polyethylene glycol; pH 6.4) warmed to 37 °C. A 0.4 mL aliquot of MES buffer containing cyclosporin A (40 nmol) was injected into the closed loop at 1.5 h after the last administration of dexamethasone. Blood samples (100–500 µL) were collected from the jugular vein and the portal vein at 45 min after *in situ* loop administration [23]. The small intestine was quickly excised, rinsed well with ice-cold saline, blotted dry and weighed, then homogenized in ice-cold saline (10%, w/v). In this study, the initial dose (40 nmol) of cyclosporin A administered into the closed loop was corrected for adsorption, which was determined by measuring the amount of cyclosporin A in the loop immediately after *in situ* administration, because cyclosporin A is readily adsorbed on the small intestinal membrane. The ratio of adsorption to dose was  $0.203 \pm 0.018$  of dose (mean  $\pm$  S.D.,  $n = 15$ ).

### 2.4. Measurement of apparent tissue-to-blood concentration ratio of M17

*mdr1a/1b* knockout mice were intravenously or orally administered with cyclosporin A (10 mg/kg). Blood samples were collected at 45 min after the administration from the jugular vein under light ether anesthesia and stored at –30 °C until assay. Mice were killed by decapitation, then the intestine and liver were quickly excised, rinsed well with ice-cold saline, blotted dry, and weighed.

### 2.5. Preparation of microsomes and plasma membrane fraction

For preparation of microsomes, the liver was homogenized in three volumes of 100 mM Tris–HCl buffer (100 mM KCl, 1 mM EDTA, pH 7.4). Microsomes were prepared as reported previously [24] and stored at –80 °C until use. The small intestine was quickly removed and washed with buffer containing 2 mM HEPES, 0.9% NaCl and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Mucosa was scraped off with a slide glass on ice and homogenized in a buffer containing 300 mM mannitol, 5 mM EDTA, 5 mM HEPES and 1 mM PMSF (pH 7.1). The homogenate was centrifuged at  $10,000 \times g$  for 20 min, and the supernatant was centrifuged at  $105,000 \times g$  for 60 min at 4 °C. The pellet was added to the buffer containing 500 mM KCl, 1 mM EDTA, 2 mM dithiothreitol (DTT) and 50 mM potassium phosphate buffer (KPB, pH 7.4) and again centrifuged at  $105,000 \times g$  for 60 min at 4 °C. The pellet was added to the buffer containing 1 mM EDTA, 2 mM DTT and 50 mM KPB (pH 7.4), then stored at –80 °C until use.

For the preparation of plasma membrane, the liver was homogenized in 10 mM Tris-HCl buffer (pH 7.5) containing 2 mM CaCl<sub>2</sub> at 4 °C. The homogenate was centrifuged at 3500 × *g* for 10 min, and the supernatant was then centrifuged at 15,000 × *g* for 30 min. The pellet was washed, resuspended in 50 mM Tris-HCl buffer (pH 7.2), and twice centrifuged at 10,000 × *g* for 5 min, then stored at -80 °C until use. The small intestine was quickly removed and washed with ice-cold isotonic saline containing 1 mM PMSF. Mucosa was scraped off with a slide glass on ice and homogenized in a buffer containing 250 mM sucrose, 50 mM Tris-HCl (pH 7.4), and 1 mM PMSF. The homogenate was centrifuged at 3000 × *g* for 10 min, and the supernatant was again centrifuged at 15,000 × *g* for 30 min. The pellet was resuspended in 0.5 mL of a buffer containing 50 mM mannitol, 50 mM Tris-HCl (pH 7.4), and 1 mM PMSF, and stored at -80 °C until use. Protein contents were measured according to the method of Lowry et al. [25].

## 2.6. Measurement of metabolic activity of CYP3A

The microsomal activity of CYP3A was measured in terms of conversion of cyclosporin A to M17, essentially according to Arlotto et al. [26]. The reaction solution (180 μL) contained cyclosporin A (final concentration 1-50 μM) and microsomal protein (final concentration 1 mg/mL) in 100 mM phosphate buffer (pH 7.4). It was pre-incubated at 37 °C for 2 min, then 20 μL of the reaction buffer (5 mM NADP<sup>+</sup>, 50 mM glucose-6-phosphate, 50 mM MgCl<sub>2</sub>, and 10 U/mL glucose-6-phosphate dehydrogenase) was added. The whole was incubated for 5 min, 100 μL of cold acetonitrile in ice bath was added, and M17 was measured using high-performance liquid chromatography (HPLC), as described below.

## 2.7. Assay of cyclosporin A and its metabolite M17

The assay for cyclosporin A and its metabolite M17 was performed according to Khoschsorur et al. [27]. Briefly, a sample of blood or tissue, 1 mL of 0.18N HCl and 4 mL of diethyl ether were added to a glass tube, but an internal standard was not used. The tube was shaken vigorously for 5 min. After centrifugation for 5 min at 3000 × *g*, the ether layer was collected in another glass tube containing 1.25 mL of 0.1N NaOH. After shaking and centrifugation, the ether layer was evaporated for 30 min at room temperature. The residue was reconstituted with 300 μL of mobile phase and a 100 μL aliquot was injected into the HPLC system (LC-9A, Shimadzu Co. Ltd., Kyoto, Japan). All samples were analyzed on an HPLC system equipped with a Waters Spherisorb 5 μm CN column (250 mm × 4.6 mm i.d., Waters Co. Ltd., MA). The absorbance was detected at a wavelength of 210 nm. The mobile phase consisted of acetonitrile:water (33:67) and was pumped at a rate of 1.2 mL/min. The limit of quantification for cyclosporin A and M17 was 30 and 5 ng/mL in 300 μL of plasma, respectively, and these calibration curves were good linear ( $r > 0.98$ ). These coefficients of the variation in the within-run ( $n = 5$ ) and the between-run (5 days) precisions were below 5%.

## 2.8. Reverse transcription-polymerase chain reaction (RT-PCR) assay

Total RNA was isolated from the liver and small intestine by using an Isogen Kit (Wako). Synthesis of cDNA from the isolated total RNA was carried out using RNase H-reverse transcriptase (GIBCO BRL, Rockville, MD). Reverse transcription (RT) reactions were carried out in 40 mM KCl, 50 mM Tris-HCl (pH 8.3), 6 mM MgCl<sub>2</sub>, 1 mM DTT, 1 mM each of dATP, dCTP, dGTP, and dTTP, 10 units of RNase inhibitor (Promega, Madison, WI), 100 pmol of random hexamer, total RNA and 200 units of the Moloney murine leukemia virus reverse transcriptase (Gibco-BRL, Berlin, Germany) in a final volume of 50 μL at 37 °C for 120 min. Polymerase chain reaction (PCR) was carried out in a final volume of 20 μL, containing 1 μL of RT reaction mixture, 50 mM KCl, 20 mM Tris-HCl (pH 8.3), 2.5 mM MgCl<sub>2</sub>, 0.2 mM each of dATP, dCTP, dGTP, and dTTP, 1 μM each of the mixed oligonucleotide primers, and 1 unit of Taq DNA polymerase (Gibco-BRL). Reported primers were used for mouse *mdr1a* (576 bp) [28], mouse *mdr1b* (486 bp) [29], mouse CYP3A (670 bp) [29], and mouse  $\beta$ -actin (456 bp) [30]. Each cycle consisted of 45 s at 94 °C, 60 s at 60 °C, and 75 s at 72 °C for *mdr1a* and *mdr1b*, 45 s at 94 °C, 60 s at 56 °C, and 75 s at 72 °C for CYP3A, and 45 s at 94 °C, 60 s at 58 °C, and 75 s at 72 °C for  $\beta$ -actin. The PCR reaction was run for 22 cycles for *mdr1a* and  $\beta$ -actin, for 26 cycles for *mdr1b*, and for 38 cycles for CYP3A.

## 2.9. SDS-PAGE and immunoblotting

SDS-PAGE and immunoblotting with peroxidase/antiperoxidase staining of the plasma membrane for P-gp and of the microsomes for CYP3A were carried out essentially as described by Laemmli [31] and Guengerich et al. [32]. The amounts of sample protein of liver and small intestine were 4 and 200 μg for CYP3A or 30 and 300 μg for P-gp, respectively. The sample protein was electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gel and transferred onto PVDF membrane filters (Millipore Co., Billerica, MA). After having been blocked with 5% skim milk, the filters were incubated overnight at 4 °C with primary antibody, mouse anti-P-gp C219 (Dako Co., Carpinteria, CA) and rabbit anti-rat CYP3A2 antibody (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan), and for 1 h with secondary antibody, anti-mouse IgG HRP-linked antibody (Cell Signaling, Beverly, MA) and mouse anti-rabbit IgG-HRP (Santa Cruz Bio., Santa Cruz, CA). Thereafter, the sample was extensively washed with phosphate-buffered saline. The immunopositive band was detected by means of a light-emitting nonradioactive detection system (Amersham International plc, Little Chalfont, Buckinghamshire, UK) with Kodak X-Omat R film (Eastman Kodak Co., Rochester, NY).

## 2.10. Data analysis

The data were analyzed using Student's *t*-test to compare the unpaired mean values of two sets of data. The number of determinations is noted in each table and figure. A value of  $P < 0.05$  or 0.01 was taken to indicate a significant difference between sets of data. The electrophoresis results were analyzed by using NIH Image software.




Fig. 1 - (a and b) Time courses of jugular venous blood concentration (a) and values of the ratio of residual cyclosporin A to dose (b) after *in situ* administration of cyclosporin A (40 nmol) into a loop of wild-type mouse upper (○) or lower (△) intestine or *mdr1a/1b* knockout mouse upper (●) or lower (▲) intestine. Each point and bar represent the mean  $\pm$  S.D. of four mice. Significantly different from the wild-type mouse upper intestine at  $^{\dagger}P < 0.05$  and  $^{\dagger\dagger}P < 0.01$ , respectively. Significantly different from the *mdr1a/1b* knockout mouse upper intestine at  $^{\#}P < 0.05$  and  $^{\#\#}P < 0.01$ , respectively. Significantly different from the wild-type mouse lower intestine at  $^{*}P < 0.05$  and  $^{**}P < 0.01$ , respectively. (a) CyA in jugular venous blood and (b) CyA in intestinal loop.

### 3. Results

#### 3.1. Site-dependent absorption of cyclosporin A from intestinal loop after an *in situ* administration

Fig. 1a shows the time courses of jugular venous blood concentration of cyclosporin A after administration of cyclosporin A (40 nmol) into upper and lower intestinal loops of wild-type and *mdr1a/1b* knockout mice. When cyclosporin A was administered into the upper intestine, its concentration rapidly increased without any significant difference between the two types of mice. In contrast, after administration of cyclosporin A into the lower intestine, the blood cyclosporin A concentration was significantly lower than that after administration into the upper intestine; moreover, the cyclosporin A concentration was significantly higher in

*mdr1a/1b* knockout mice than in wild-type mice. As shown in Fig. 1b, the residual amount of cyclosporin A in the intestinal loop was essentially a mirror image of the change in the blood concentration, indicating that the absorption of cyclosporin A was higher in the upper intestine than in the lower intestine in both types of mice, and that the absorption from the lower intestine was higher in *mdr1a/1b* knockout mice than in wild-type mice.

#### 3.2. Effect of dexamethasone on absorption of cyclosporin A and its metabolite M17 from intestinal loop after an *in situ* administration

Fig. 2 shows the concentrations of cyclosporin A (a) and its major metabolite M17 (b) in portal venous blood and the ratio of residual cyclosporin A to dose (c) in upper and lower




Fig. 2 - The concentrations of cyclosporin A (a) and M17 (b) in portal venous blood and the ratio of residual cyclosporin A to dose (c) in an upper or lower intestinal loop at 45 min after *in situ* administration of cyclosporin A (40 nmol) into an upper or lower intestinal loop of wild-type or *mdr1a/1b* knockout mice with or dexamethasone treatment (75 mg/kg, daily, 7 times), at 1.5 h after the last administration. Each column and bar represent the mean  $\pm$  S.D. of four mice. Significantly different at  $^{\dagger}P < 0.05$  and  $^{\dagger\dagger}P < 0.01$ , respectively. (NS) no significant difference. (□) Wild-type without dexamethasone treatment; (▨) wild-type with dexamethasone treatment; (▩) *mdr1a/1b* knockout without dexamethasone treatment; (■) *mdr1a/1b* knockout with dexamethasone treatment.

273 intestinal loops at 45 min after *in situ* administration of  
274 cyclosporin A (40 nmol) in wild-type and *mdr1a/1b* knockout  
275 mice treated with or without dexamethasone.

276 There was no significant difference in the portal venous  
277 blood concentrations of cyclosporin A after administration into  
278 the upper intestinal loop between the untreated control groups  
279 of both types of mice, but the concentration after administra-  
280 tion into the lower intestinal loop of *mdr1a/1b* knockout mice  
281 was significantly higher than that in the case of wild-type mice.  
282 These findings were consistent with the data on jugular venous  
283 blood concentration of cyclosporin A after administration of  
284 cyclosporin A into the intestinal loops (Fig. 1a).

285 In mice treated with dexamethasone, the blood concentra-  
286 tion of cyclosporin A after administration into the upper  
287 intestinal loop was significantly decreased in wild-type mice,  
288 but was not changed in *mdr1a/1b* knockout mice. When  
289 cyclosporin A was administered into the lower loop, its blood  
290 concentration was not significantly decreased by dexametha-  
291 sone treatment in both types of mice (Fig. 2a). Fig. 2c shows  
292 the ratio of residual cyclosporin A to the dose in upper and lower  
293 intestinal loops after administration of cyclosporin A. The  
294 dexamethasone treatment significantly increased the residual  
295 ratio of cyclosporin A in the upper intestinal loop of wild-type  
296 mice, but not *mdr1a/1b* knockout mice. Thus, it appears that  
297 dexamethasone inhibited cyclosporin A absorption from the  
298 upper intestine of wild-type mice, but not P-gp-deficient mice.

299 As regards the metabolite, the portal venous blood  
300 concentrations of M17 after administration of cyclosporin A  
301 into the upper intestinal loop were similar in both types of  
302 mice; however, dexamethasone treatment significantly  
303 decreased the M17 concentration in wild-type mice, but not  
304 the knockout mice. In the case of administration into the lower  
305 intestinal loop, the blood concentrations of M17 in both types  
306 of mice were very much lower than those after administration  
307 into the upper intestinal loop, and were significantly increased  
308 by dexamethasone treatment (Fig. 2b).

309 Fig. 3 shows the values of the concentration ratio of M17 to  
310 cyclosporin A in jugular and portal venous blood at 45 min  
311 after administration of cyclosporin A (40 nmol) into the small  
312 intestine loop in *mdr1a/1b* knockout mice treated with or  
313 without dexamethasone. After administration into the upper  
314 intestinal loop, there was no significant difference between  
315 the values of the M17/cyclosporin A ratio in the untreated  
316 control group and the dexamethasone group, and in jugular  
317 blood and portal blood. However, after administration into the  
318 lower intestinal loop, the value of the M17/cyclosporin A ratio  
319 of the dexamethasone group was about seven times larger  
320 than that in the untreated control group in both jugular and  
321 portal blood. The M17/cyclosporin A ratios in portal blood  
322 were significantly higher than those in jugular blood in both groups.

### 3.3. Apparent tissue-to-blood concentration ratio of M17 in small intestine and liver after intravenous or oral administration of cyclosporin A

326 Fig. 4 shows the values of the apparent tissue-to-blood  
327 concentration ratio ( $K_{b,app}$ ) of M17 for the upper small  
328 intestine, lower small intestine and liver of *mdr1a/1b* knockout  
329 mice at 45 min after an intravenous or oral administration of  
330 cyclosporin A (10 mg/kg).




Fig. 3 – The value of the M17/cyclosporin A ratio in jugular or portal venous blood at 45 min after *in situ* administration of cyclosporin A (40 nmol) into the upper or lower intestinal loop of *mdr1a/1b* knockout mice with (■) or without (▨) dexamethasone treatment (75 mg/kg, daily, 7 times), at 1.5 h after the last administration. Each column and bar represent the mean  $\pm$  S.D. of four mice. Significantly different from the each group of jugular venous blood at #P < 0.05 and ##P < 0.01, respectively.




Fig. 4 – The values of the apparent tissue-to-blood concentration ratio ( $K_{b,app}$ ) of M17 in the upper intestine, lower intestine and liver at 45 min after i.v. (▨) or p.o. (■) administration of cyclosporin A (10 mg/kg) in *mdr1a/1b* knockout mice. Each column and bar represent the mean  $\pm$  S.D. of four mice. Significantly different from i.v. administration at P < 0.01.

There was no difference between the  $K_{b,app}$  values of M17 for the upper and lower intestine after intravenous administration, but the  $K_{b,app}$  value for the upper intestine after oral administration was very much higher than that after intravenous administration, while that for the lower intestine was very much lower. There was no difference between the  $K_{b,app}$  values for the liver after intravenous and oral administrations, but the value after intravenous administration was about two to three times higher than those of the two regions of small intestine. The tissue concentration of unchanged cyclosporin A was not evaluated, because of the high tissue adsorption of the drug in the small intestine after oral administration.

#### 3.4. Expression of P-gp and CYP3A in small intestine and liver

Fig. 5 shows the results of quantitation of RT-PCR *mdr1a*, *mdr1b* and CYP3A mRNAs in the upper and lower intestine and liver in wild-type and *mdr1a/1b* knockout mice treated with or without dexamethasone. In the untreated wild-type group, the expression of *mdr1a* mRNA was less in the upper intestine than in the lower intestine, while that of *mdr1b* mRNA was in the opposite relationship. But, the expression levels of *mdr1b*

mRNA in the lower intestine and the liver of wild-type mice were much lower than those of *mdr1a* mRNA, and the influence of dexamethasone treatment on the expression of *mdr1b* mRNA could not be observed clearly. Treatment with dexamethasone clearly altered the expression of *mdr1a* mRNA in the upper intestine. The expression of CYP3A mRNA in the untreated group of wild-type and knockout mice was higher in the upper intestine than in the lower intestine. Dexamethasone induced CYP3A mRNA expression more strongly in the lower intestine than in the upper intestine. Dexamethasone also induced *mdr1a* and CYP3A mRNA expression in the liver. The expression levels of P-gp and CYP3A proteins and the effect of dexamethasone were confirmed by Western blot analysis using tissues of wild-type mice (Fig. 6). The protein levels of P-gp in the upper intestine and liver were elevated to about four and three times the untreated control level by dexamethasone treatment, respectively, but the level in the lower intestine was hardly changed by dexamethasone. On the other hand, the protein levels of CYP3A in the lower intestine and liver were elevated to about five and two times the control level by dexamethasone treatment, respectively, while the level in the upper intestine was little elevated.






Fig. 5 - (a and b) Effects of dexamethasone on the expression of *mdr1a*, *mdr1b* and CYP3A mRNAs in upper intestine, lower intestine and liver of wild-type and *mdr1a/1b* knockout mice with or without dexamethasone treatment, at 1.5 h after the last dexamethasone treatment. (a) Mice were given successive i.p. administrations of dexamethasone (75 mg/kg, daily, 7 times). The sizes of the reverse transcriptase-polymerase chain reaction (RT-PCR) products are 576 bp (*mdr1a*), 486 bp (*mdr1b*), and 670 bp (CYP3A). Lanes 1-3: no treatment; lanes 4-6: dexamethasone treatment. (b) Relative expression of *mdr1a* and CYP3A mRNAs of wild-type and *mdr1a/1b* knockout mice with or without dexamethasone treatment. Each column and bar represent the mean  $\pm$  S.D. of three mice. Significantly different from the dexamethasone-untreated mice at  $^*P < 0.05$  and  $^{**}P < 0.01$ , respectively. (□) Wild-type without dexamethasone treatment; (▤) wild-type with dexamethasone treatment; (▨) *mdr1a/1b* knockout without dexamethasone treatment; (▩) *mdr1a/1b* knockout with dexamethasone treatment.



**Fig. 6 – Western blot analysis of P-gp (a) and CYP3A (b) proteins in the upper intestine, lower intestine and liver of wild-type mice with or without dexamethasone treatment, at 1.5 h after the last dexamethasone treatment. Mice were given successive i.p. administrations of dexamethasone (75 mg/kg, daily, 7 times). Lanes 1–3: no treatment; lanes 4–6: dexamethasone treatment.**



**Fig. 7 – (a–c) Enzyme activity of microsomal formation of M17 from cyclosporin A. Microsomes were obtained from isolated small intestine of wild-type mice (a), small intestine of *mdr1a/1b* knockout mice (b) and liver (c) of wild-type and *mdr1a/1b* knockout mice with (closed symbol) or without (open symbol) dexamethasone treatment (75 mg/kg, daily, 7 times), at 1.5 h after the last administration. Each symbol represents the mean  $\pm$  S.D. of four mice. (a and b) (○) Upper intestine; (△) lower intestine; (c) (○) wild-type mice; (△) *mdr1a/1b* knockout mice.**

### 3.5. Enzyme activity of CYP3A in small intestine and liver

Fig. 7 shows the activity for *in vitro* formation of M17 from cyclosporin A in microsome preparations from the small intestine and liver of wild-type and *mdr1a/1b* knockout mice treated with or without dexamethasone. There was little difference in the activity of the small intestine or liver between untreated wild-type and *mdr1a/1b* knockout mice. However, the activities in the upper intestine of both types of mice were much higher than those in the lower intestine. Further, the activities in the liver of both types of untreated mice were about 20 times higher than those in the upper intestine. Dexamethasone treatment increased the activities in the upper intestine and liver of both types of mice by about 3- and 25-fold, respectively. Further, dexamethasone treatment increased the activities in the lower intestine, which almost lacked metabolic activity in untreated mice, to the levels seen in the upper intestine of untreated mice.

## 4. Discussion

We previously suggested that P-gp had little influence on the intestinal absorption of cyclosporin A under physiological conditions, whereas after induction by dexamethasone, it

markedly inhibited the oral bioavailability in mice; however, the contribution of CYP3A to the intestinal absorption was not evaluated [21]. In that study, we found that the magnitude of *mdr1a* mRNA was in the order of ileum > jejunum > duodenum, while that of CYP3A mRNA was in the opposite order; further, of cyclosporin A under physiological conditions, whereas after induction by dexamethasone induced these mRNAs more strongly in the intestinal regions where expression was weaker in untreated animals. Thorn et al. [33] reported regarding the expression of CYP and *mdr* mRNAs along the human gastrointestinal tract. Then, the pattern of expression of these mRNAs in duodenum, jejunum and ileum of human was well similar to those of our mice.

In the present study, in order to clarify the intestinal site-specific roles and functions of P-gp and the cyclosporin A-metabolizing enzyme CYP3A in cyclosporin A absorption, we firstly confirmed that the expression of P-gp and CYP3A at the mRNA and protein levels in the upper and lower small intestine is fundamentally the same as the above-described results (Figs. 5 and 6).

Yamaguchi et al. reported that the intestinal secretion of grepafloxacin in *mdr1a/1b* knockout mice is decreased to 62% of that in wild-type mice, and pre-administration of cyclosporin A to wild-type mice resulted in comparable secretion to that in *mdr1a/1b* knockout mice with or without cyclosporin A



pre-administration [34]. The ratio of intestinal secretion to dose of grepafloxacin in both types of mice was in the range of 5–7%. Similarly, we found that the values of the ratio of intestinal secretion of cyclosporin A to dose over 45 min after an i.v. administration of cyclosporin A (10 mg/kg) in wild-type and *mdr1a/1b* knockout mice were  $0.8 \pm 0.2$  and  $0.6 \pm 0.2\%$  (mean  $\pm$  S.D.,  $n = 4$ ), respectively. Therefore, we considered that the intestinal secretion of cyclosporin A is negligible in the context of this intestinal loop study.

We have shown here that (1) the absorption of cyclosporin A from the upper intestine is very much higher than that from the lower intestine; (2) in the upper intestine, there is no significant difference in absorption of cyclosporin A between wild-type and *mdr1a/1b* knockout mice, whereas in the lower intestine, absorption of cyclosporin A in *mdr1a/1b* knockout mice was higher than that of wild-type mice; (3) dexamethasone treatment inhibited the absorption of cyclosporin A from the upper intestine, but not from the lower intestine, in wild-type mice; (4) the blood concentration of the major metabolite M17 was higher after administration of cyclosporin A into the upper intestine than into the lower intestine and (5) the blood concentration of M17 was lowered by dexamethasone after administration of cyclosporin A into the upper intestine in wild-type mice, but not *mdr1a/1b* knockout mice, whereas it was increased by dexamethasone after administration of cyclosporin A into the lower intestine in both types of mice (Figs. 1 and 2). Furthermore, P-gp was expressed more strongly in the lower intestine than in the upper intestine at both the mRNA and protein levels, and the protein level in the upper intestine was strongly induced by cyclosporin A under physiological conditions, whereas after induction by dexamethasone. In contrast, CYP3A was expressed more strongly in the upper intestine than in the lower intestine in terms of both protein level and metabolic activity, and it was more strongly induced by dexamethasone in the lower intestine than in the upper intestine. These findings represent a significant extension of our previous study [21], and we confirmed that cyclosporin A was absorbed predominantly from the upper intestine in mice, as reported by Cakaloglu et al. [35].

It is well known that the major metabolite of cyclosporin A is M17, rather than M1 or M21, which are generated by CYP3A in intestinal or hepatic microsomes [36,37]. Cyclosporin A may be metabolized to M17 during transport in mucosal epithelial cells of upper intestine (Figs. 2 and 4). Although the cyclosporin A-metabolizing activity in the upper intestine is only about one-third of that in the liver, the activity is increased to the level in the liver by dexamethasone treatment (Fig. 7). After dexamethasone treatment, the formation of M17 was significantly increased in the lower intestine (Fig. 2c). Moreover, it is suggested that cyclosporin A is extensively metabolized to M17 in the small intestine rather than in the liver after oral administration of cyclosporin A, since the ratio of M17/cyclosporin A was higher in portal blood than in jugular blood, irrespective of dexamethasone treatment and administration route (Fig. 3). We consider that cyclosporin A undergoes a first-pass effect from CYP3A in the upper intestine, rather than in the liver.

*mdr1a/1b* knockout mice have similar CYP3A activity, but are deficient in P-gp, compared with the wild-type mice. Schuetz et al. [38] has been reported that CYP3A catalytic

activity measured as midazolam 1'- and 4-hydroxylation in liver microsomes from these knockout mice revealed a rank order of activities with  $mdr1a/1b(-/-) > mdr1a(-/-) > mdr1b(-/-) > mdr1a/1b(+/+)$ . But we evaluated the CYP3A activity by microsomal formation of M17 from cyclosporin A. However, when cyclosporin A was orally administered, the bioavailability in *mdr1a/1b* knockout mice was not different from that in wild-type mice. Thus, we concluded that P-gp plays only a small role in the intestinal absorption of cyclosporin A under physiological conditions [21]. In the present study, after administration of cyclosporin A into the regional intestinal loops, the blood concentrations of cyclosporin A and metabolite M17 were similar in *mdr1a/1b* knockout mice and wild-type mice, except that the blood concentration of cyclosporin A after administration into the lower intestine was higher in *mdr1a/1b* knockout mice than in wild-type mice (Fig. 2a). This may be due to lack of the absorption barrier function of P-gp in *mdr1a/1b* knockout mice, although the lower intestine is only a minor absorption site of cyclosporin A. After dexamethasone treatment, P-gp significantly affected the bioavailability of cyclosporin A [21], because of strong induction of P-gp in the upper intestine. As shown in Fig. 2b, dexamethasone treatment lowered the blood concentration of M17 after administration of cyclosporin A into the upper intestinal loop of wild-type mice. This suggests that M17 is also a substrate of P-gp. Therefore, there may be complex interactions among intact cyclosporin A, its metabolites, P-gp, and metabolizing enzymes at the absorption sites.

In conclusion, we have confirmed that cyclosporin A is absorbed predominantly from the upper intestine in mice. CYP3A and P-gp are highly expressed and function predominantly in the upper intestine and the lower intestine, respectively, but are strongly induced by high-dose steroid hormone at the sites where their expression is weak in untreated animals. Therefore, the oral bioavailability of cyclosporin A is primarily controlled by CYP3A in the upper small intestine of mice under physiological conditions, whereas after treatment with inducers, P-gp in the upper intestine also plays a significant role as an absorption barrier to cyclosporin A.

## REFERENCES

- [1] Ohlman S, Lindholm A, Hagglund H, Sawe J, Kahan BD. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. *Eur J Clin Pharmacol* 1993;44:265–9.
- [2] Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. *Transplant Proc* 2004;36:378–91.
- [3] Abendroth D. Experience with therapeutic drug monitoring of cyclosporine. *Transplant Proc* 2004;36:426–9.
- [4] Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J Clin Invest* 1999;104:147–53.
- [5] Nakayama A, Saitoh H, Oda M, Takada M, Aungst BJ. Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. *Eur J Pharm Sci* 2000;11:317–24.
- [6] Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and seville orange juice on the

- 539 pharmacokinetics of dexamethasone tromethorphan: the  
540 role of gut CYP3A and P-glycoprotein. *Life Sci* 2002;71:  
541 1149-60.
- [7] Saitoh H, Saikachi Y, Kobayashi M, Yamaguchi M, Oda M,  
542 Yuhki Y, et al. Limited interaction between tacrolimus and  
543 P-glycoprotein in the rat small intestine. *Eur J Pharm Sci*  
544 2006;28:34-42.
- [8] Zimmerman JJ. Exposure-response relationships and drug  
545 interactions of sirolimus. *AAPS J* 2004;6:e28.
- [9] Tamai I, Safa AR. Competitive interaction of cyclosporins  
546 with the Vinca alkaloid-binding site of P-glycoprotein in  
547 multidrug-resistant cells. *J Biol Chem* 1990;265:16509-13.
- [10] Watkins PB. Drug metabolism by cytochromes P450 in the  
548 liver and small bowel. *Gastroenterol Clin North Am*  
549 1992;21:511-26.
- [11] Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK,  
550 Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein  
551 (mdr1) in interpatient variation in the oral bioavailability of  
552 cyclosporine. *Clin Pharmacol Ther* 1997;62:248-60.
- [12] Watkins PB, Wrighton SA, Schuetz EG, Molowa DT,  
553 Guzelian PS. Identification of glucocorticoid-inducible  
554 cytochromes P-450 in the intestinal mucosa of rats and  
555 man. *J Clin Invest* 1987;80:1029-36.
- [13] de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH.  
556 Cytochrome P 450 isoenzymes, epoxide hydrolase and  
557 glutathione transferases in rat and human hepatic  
558 and xanthine oxidase in rat and human hepatic  
559 and xanthine oxidase in rat and human hepatic  
560 and xanthine oxidase in rat and human hepatic  
561 and xanthine oxidase in rat and human hepatic  
562 and xanthine oxidase in rat and human hepatic  
563 and xanthine oxidase in rat and human hepatic  
564 and xanthine oxidase in rat and human hepatic  
565 and xanthine oxidase in rat and human hepatic  
566 and xanthine oxidase in rat and human hepatic  
567 and xanthine oxidase in rat and human hepatic  
568 and xanthine oxidase in rat and human hepatic  
569 and xanthine oxidase in rat and human hepatic  
570 and xanthine oxidase in rat and human hepatic  
571 and xanthine oxidase in rat and human hepatic  
572 and xanthine oxidase in rat and human hepatic  
573 and xanthine oxidase in rat and human hepatic  
574 and xanthine oxidase in rat and human hepatic  
575 and xanthine oxidase in rat and human hepatic  
576 and xanthine oxidase in rat and human hepatic  
577 and xanthine oxidase in rat and human hepatic  
578 and xanthine oxidase in rat and human hepatic  
579 and xanthine oxidase in rat and human hepatic  
580 and xanthine oxidase in rat and human hepatic  
581 and xanthine oxidase in rat and human hepatic  
582 and xanthine oxidase in rat and human hepatic  
583 and xanthine oxidase in rat and human hepatic  
584 and xanthine oxidase in rat and human hepatic  
585 and xanthine oxidase in rat and human hepatic  
586 and xanthine oxidase in rat and human hepatic  
587 and xanthine oxidase in rat and human hepatic  
588 and xanthine oxidase in rat and human hepatic  
589 and xanthine oxidase in rat and human hepatic  
590 and xanthine oxidase in rat and human hepatic  
591 and xanthine oxidase in rat and human hepatic  
592 and xanthine oxidase in rat and human hepatic  
593 and xanthine oxidase in rat and human hepatic  
594 and xanthine oxidase in rat and human hepatic  
595 and xanthine oxidase in rat and human hepatic  
596 and xanthine oxidase in rat and human hepatic  
597 and xanthine oxidase in rat and human hepatic  
598 and xanthine oxidase in rat and human hepatic  
599 and xanthine oxidase in rat and human hepatic  
600 and xanthine oxidase in rat and human hepatic  
601 and xanthine oxidase in rat and human hepatic  
602 and xanthine oxidase in rat and human hepatic  
603 and xanthine oxidase in rat and human hepatic  
604 and xanthine oxidase in rat and human hepatic  
605 and xanthine oxidase in rat and human hepatic  
606 and xanthine oxidase in rat and human hepatic  
607 and xanthine oxidase in rat and human hepatic
- endothelin and neurokinin receptor antagonists at the rat  
portal and jugular veins after oral administration  
as a tool in peptide drug design. *Drug Des Discov*  
1994;12:121-8.
- [24] Kamataki T, Kitagawa H. Effects of lyophilization and  
storage of rat liver microsomes on activity of aniline  
hydroxylase, contents of cytochrome b5 and cytochrome P-  
450 and aniline-induced P-450 difference spectrum. *Jpn J  
Pharmacol* 1974;24:195-203.
- [25] Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein  
measurement with Folin phenol reagent. *J Biol Chem*  
1951;193:265-75.
- [26] Arlotto MP, Trant JM, Estabrook RW. Measurement of  
steroid hydroxylation reactions by high-performance liquid  
chromatography as indicator of P450 identity and function.  
*Methods Enzymol* 1991;206:454-62.
- [27] Khoschror G, Semmelrock HJ, Rodl S, Auer T, Petek W,  
Iberer F, et al. Rapid, sensitive high-performance liquid  
chromatographic method for the determination of  
cyclosporin A and its metabolites M1, M17 and M21. *J  
Chromatogr B Biomed Sci Appl*  
1997;690:367-72.
- [28] Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros  
P, et al. The three mouse multidrug resistance (mdr) genes  
are expressed in a tissue-specific manner in normal mouse  
tissues. *Mol Cell Biol* 1989;9:1346-50.
- [29] Seree E, Villard PH, Hever A, Guigal N, Puyoo F, Charvet B,  
et al. Modulation of MDR1 and CYP3A expression by  
dexamethasone amethasone: evidence for an inverse  
regulation in adrenals. *Biochem Biophys Res Commun*  
1998;252:392-5.
- [30] Waki Y, Miyamoto K, Kasugai S, Ohya K. Osteoporosis-like  
changes in Walker carcinoma 256-bearing rats, not  
accompanied with hypercalcemia or parathyroid hormone-  
related protein production. *Jpn J Cancer Res* 1995;86:470-6.
- [31] Laemmli UK. Cleavage of structure proteins during the  
assembly of the head of bacteriophage T4. *Nat Lond*  
1970;227:680-5.
- [32] Guengerich FP, Wang P, Davidson NK. Estimation of  
isozymes of microsomal cytochrome P-450 in rats, rabbits  
and humans using immunochemical staining coupled with  
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.  
*Biochemistry* 1982;21:1698-706.
- [33] Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L.  
Cytochromes P450 and MDR1 mRNA expression along the  
human gastrointestinal tract. *Br J Clin Pharmacol*  
2005;60:54-60.
- [34] Yamaguchi H, Yano I, Saito H, Inui K. Pharmacokinetic role  
of P-glycoprotein in oral bioavailability and intestinal  
secretion of grepafloxacin in vivo. *J Pharmacol Exp Ther*  
2002;300:1063-9.
- [35] Cakaloglu Y, Marinos G, Marsden J, Peters TJ, Williams R,  
Tredger JM. Localization of cyclosporin A absorption in rat  
small bowel and the effect of bile. *Clin Sci* 1993;84:675-9.
- [36] Vickers AE, Fisher RL, Brendel K, Guertler J, Dannecker R,  
Keller B, et al. Sites of biotransformation for the cyclosporin  
derivative SDZ IMM 125 using human liver and kidney  
slices and intestine. *Drug Metab Dispos* 1995;23:327-33.
- [37] Brozmanova H, Grundmann M, Safarcik K, Jegorov A. High-  
performance liquid chromatographic method for  
therapeutic drug monitoring of cyclosporine A and its two  
metabolites in renal transplant patients. *J Chromatogr B  
Biomed Sci* 2000;749:93-100.
- [38] Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen  
L, Relling MV, et al. Altered expression of hepatic  
cytochromes P-450 in mice deficient in  
one or more mdr1 genes. *Mol Pharmacol*  
2000;57:188-97.